The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incidence of posttransplantation lymphoproliferative disorder (PTLD) following allogeneic blood or marrow transplantation (alloBMT) using post-transplantation cyclophosphamide (PT-Cy) for graft-versus-host disease (GVHD) prophylaxis.
Jennifer Ann Kanakry
No relevant relationships to disclose
Yvette L. Kasamon
No relevant relationships to disclose
Lode J. Swinnen
No relevant relationships to disclose
Javier Bolanos-Meade
No relevant relationships to disclose
Douglas Gladstone
No relevant relationships to disclose
Heather J. Symons
No relevant relationships to disclose
Huzefa J. Mogri
No relevant relationships to disclose
Christopher George Kanakry
No relevant relationships to disclose
Christopher D Gocke
No relevant relationships to disclose
Leo Luznik
No relevant relationships to disclose
Ephraim Joseph Fuchs
No relevant relationships to disclose
Richard J. Jones
No relevant relationships to disclose
Richard F. Ambinder
No relevant relationships to disclose